• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

NEWS

Fixed-duration glofitamab in patients with relapsed or refractory follicular lymphoma: Results from a Phase 1/2 study

View in PubMed
18 de November de 2026/in Sureda's & Farre's Lab/by

Hemasphere. 2026 Nov 17;10(11):e70531. doi: 10.1002/hem3.70531. eCollection 2026 Nov.

ABSTRACT

More effective options are needed to personalize treatment for relapsed/refractory (R/R) follicular lymphoma (FL) by balancing efficacy, safety, and accessibility. We report efficacy and safety of glofitamab, a CD20xCD3 T-cell engaging bispecific antibody, from a Phase 1/2 study in patients with R/R FL after ≥2 prior therapies. Overall, 61 patients were enrolled at the recommended Phase 2 dose of glofitamab (target dose, 30 mg). The overall response rate was 85.2% (95% confidence interval [CI] 73.8-93.0), and complete response (CR) rate was 77.0% (95% CI 64.5-86.9). After a median follow-up of 29.3 months, the median duration of CR was 40.2 months (95% CI 20.0-not estimable [NE]). Median progression-free survival was 21.4 months (95% CI 11.4-NE) and the 24-month progression-free survival rate was 49.0%. The most common adverse event was cytokine release syndrome (62.3%; all Grade ≤2). Immune effector cell-associated neurotoxicity syndrome rates were low (6.5%; Grade ≤2, 4.9%; Grade 3, 1.6%). Patients had high rates of undetectable minimal residual disease at their first tumor assessment (Cycle 3) (76.3%), which lasted beyond the end-of-treatment (EOT). Immuno-recovery occurred 12-18 months after EOT in patients with ongoing remission, and T-cell count was not impacted by glofitamab treatment. Fixed-duration glofitamab monotherapy induces durable responses with manageable safety. Glofitamab represents an accessible off-the-shelf therapy for patients with R/R FL, including those with high-risk disease, and an important combination partner for the treatment of R/R FL. ClinicalTrials.gov identifier: NCT03075696.

PMID:43048280 | PMC:PMC13776797 | DOI:10.1002/hem3.70531

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-11-18 11:00:002026-11-18 11:00:00Fixed-duration glofitamab in patients with relapsed or refractory follicular lymphoma: Results from a Phase 1/2 study

Filter by categories

  • Alemany’s & Piulats’s lab (135)
  • Antolin's lab (37)
  • Aytes's Lab (25)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (112)
  • Sin categoría (12)
  • Sureda's & Farre's Lab (323)
  • Viñals's lab (114)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Bridging to CD19 CAR T-cell therapy for large B-cell lymphoma: An analysis of...
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}